Request FDA to refrain from receiving any ANDA that references Imvexxy (NDA 208564) unless, for each strength that is Q1/Q2 and Q3 similar to Imvexxy
🏛 Food and Drug Administration (FDA)FDA-2018-P-4714
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.